Nanopublication: RAx6t2VGzX

Full identifier: http://purl.org/np/RAx6t2VGzXNdaSHysTx1kBRR3ZBpazJFMj9qXiLCvCANk

Raw formats: TriG(html,txt), JSON-LD(txt), N-Quads(txt), XML(txt)

Checking for updates...

 RAx6t2VGzX comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAx6t2VGzX...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "oseltamivir phosphate for oral suspension is an influenza neuraminidase inhibitor nai indicated for treatment of acute uncomplicated influenza a and b in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours 1 1 prophylaxis of influenza a and b in patients 1 year and older 1 2 limitations of use not a substitute for annual influenza vaccination 1 3 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use 1 3 not recommended for patients with end stage renal disease not undergoing dialysis 1 3 oseltamivir phosphate for oral suspension is indicated for the treatment of acute uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours oseltamivir phosphate for oral suspension is indicated for the prophylaxis of influenza a and b in patients 1 year and older oseltamivir phosphate for oral suspension is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices influenza viruses change over time emergence of resistance substitutions could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate for oral suspension see microbiology 12 4 oseltamivir phosphate for oral suspension is not recommended for patients with end stage renal disease not undergoing dialysis see dosage and administration 2 4 use in specific populations 8 6" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAx6t2VGzX... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-12T16:43:48.217+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAx6t2VGzX... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAx6t2VGzX... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAx6t2VGzX... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAx6t2VGzX...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAx6t2VGzX... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAx6t2VGzX...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 12 Jun 2021, 14:43:48 UTC

show references